Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions.

PURPOSE To prospectively evaluate accuracy of gadobenate dimeglumine-enhanced magnetic resonance (MR) mammography for depiction of synchronous contralateral breast cancer in patients with newly diagnosed unilateral breast cancer or high-risk lesions, with histologic analysis or follow-up as reference. MATERIALS AND METHODS The study had ethics committee approval; all patients provided written informed consent. One hundred eighteen consecutive women (mean age, 52 years) with unilateral breast cancer or high-risk lesions and negative findings in the contralateral breast at physical examination, ultrasonography, and conventional mammography underwent gadobenate dimeglumine-enhanced 1.5-T MR mammography. Transverse three-dimensional T1-weighted gradient-echo images were acquired before and at 0, 2, 4, 6, and 8 minutes after gadobenate dimeglumine administration (0.1 mmol per kilogram body weight). Breast Imaging Reporting and Data System (BI-RADS) was used to categorize breast density and the level of suspicion for malignant contralateral breast lesions. Results were compared with histologic findings. Sensitivity, specificity, accuracy, and positive and negative predictive values for contrast-enhanced MR mammography were evaluated. RESULTS Contrast-enhanced MR mammography revealed contralateral lesions in 28 (24%) of 118 patients. Twenty-four lesions were detected in patients with dense breasts (BI-RADS breast density category III or IV). Lesions in eight (29%) of 28 patients were BI-RADS category 4; patients underwent biopsy. Lesions in 20 (71%) patients were BI-RADS category 5; patients underwent surgery. At histologic analysis, 22 lesions were confirmed as malignant; six lesions were fibroadenomas. No false-negative lesions were detected; none of the fibroadenomas were BI-RADS category 5. The sensitivity, specificity, accuracy, and positive and negative predictive values of contrast-enhanced MR mammography for depiction of malignant or high-risk contralateral lesions were 100%, 94%, 95%, 79%, and 100%, respectively. Follow-up findings (12-24 months) confirmed absence of contralateral lesions in 90 of 118 patients with negative contrast-enhanced MR mammographic findings in the contralateral breast. CONCLUSION Contrast-enhanced MR mammography is accurate for detection of synchronous contralateral cancer or high-risk lesions in patients with newly diagnosed breast cancer or high-risk lesions.

[1]  K. Malone,et al.  Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988‐2001 , 2006, Cancer.

[2]  David Gur,et al.  Screening mammography: do women prefer a higher recall rate given the possibility of earlier detection of cancer? , 2006, Radiology.

[3]  F. Schick,et al.  Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla , 2006, Investigative radiology.

[4]  L. Liberman,et al.  Does size matter? Positive predictive value of MRI-detected breast lesions as a function of lesion size. , 2006, AJR. American journal of roentgenology.

[5]  I. Imaz,et al.  Overall Breast Density in MR Mammography: Diagnostic and Therapeutic Implications in Breast Cancer , 2006, Journal of computer assisted tomography.

[6]  C. Boetes,et al.  Screening women at increased risk with MRI , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.

[7]  R. Fimmers,et al.  Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Catalano,et al.  Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine. , 2005, Radiology.

[9]  Alessandro Carriero,et al.  Gadobenate dimeglumine-enhanced MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vascularity. , 2005, Radiology.

[10]  L. Philpotts.  Will improved vascular mapping achieved with gadobenate dimeglumine aid in interpretation of breast MR images? , 2005, Radiology.

[11]  M. Prokop,et al.  Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. , 2005, Radiology.

[12]  Massimo Bazzocchi,et al.  Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in Fatty and dense breasts using the whole-breast pathologic examination as a gold standard. , 2004, AJR. American journal of roentgenology.

[13]  H. D. de Koning,et al.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. , 2004, The New England journal of medicine.

[14]  Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary? , 2004, Radiology.

[15]  Robert E. Lenkinski,et al.  The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy , 2001, Breast Cancer Research and Treatment.

[16]  Matthijs Oudkerk,et al.  First experiences in screening women at high risk for breast cancer with MR imaging , 2000, Breast Cancer Research and Treatment.

[17]  Michael Laniado,et al.  MR imaging of the contralateral breast in patients after breast-conserving therapy , 2004, European Radiology.

[18]  Peter B Barker,et al.  Benign and malignant breast lesions: diagnosis with multiparametric MR imaging. , 2003, Radiology.

[19]  M. Oudkerk,et al.  Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. , 2003, AJR. American journal of roentgenology.

[20]  Mitchell D Schnall,et al.  MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. , 2003, Radiology.

[21]  Jennifer B Kaplan,et al.  MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. , 2003, AJR. American journal of roentgenology.

[22]  Robert C. Brasch,et al.  Macromolecular contrast agents for MR mammography: current status , 2003, European Radiology.

[23]  D. Kopans,et al.  Occult Contralateral Breast Carcinoma Incidentally Detected by Breast Magnetic Resonance Imaging , 2002, The breast journal.

[24]  F. Demirkazık.  MR imaging features of breast lymphoma. , 2002, European journal of radiology.

[25]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M D Schnall,et al.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. , 2001, Radiology.

[27]  C K Kuhl,et al.  Dynamic image interpretation of MRI of the breast , 2000, Journal of magnetic resonance imaging : JMRI.

[28]  P. Hasselgren,et al.  Bilateral synchronous breast cancer: mode of detection and comparison of histologic features between the 2 breasts. , 2000, Surgery.

[29]  P. Porter,et al.  Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. , 2000, Journal of the National Cancer Institute.

[30]  E A Sickles,et al.  Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. , 2000, AJR. American journal of roentgenology.

[31]  T. Helbich,et al.  Contrast-enhanced magnetic resonance imaging of the breast. , 2000, European journal of radiology.

[32]  M. Noguchi,et al.  Breast cancer in dense breast: Detection with contrast‐enhanced dynamic MR imaging , 2000, Journal of magnetic resonance imaging : JMRI.

[33]  W. Thompson,et al.  Epidemiology of contralateral breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[35]  S G Orel,et al.  Differentiating benign from malignant enhancing lesions identified at MR imaging of the breast: are time-signal intensity curves an accurate predictor? , 1999, Radiology.

[36]  J F Debatin,et al.  Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. , 1998, The British journal of radiology.

[37]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[38]  C. Piccoli,et al.  Contrast-enhanced breast MRI: factors affecting sensitivity and specificity , 1997, European Radiology.

[39]  E. Merkle,et al.  MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma. , 1997, Journal of computer assisted tomography.

[40]  C. Claussen,et al.  Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. , 1997, Radiology.

[41]  G Lutterbey,et al.  Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.

[42]  S. Higano,et al.  Correlation of lesions in the hippocampal region noted on MR images with clinical features , 1997, European Radiology.

[43]  M. Helvie,et al.  Mammographic appearance of cancer in the opposite breast: comparison with the first cancer. , 1996, AJR. American journal of roentgenology.

[44]  J O Barentsz,et al.  Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. , 1995, Radiology.

[45]  S. Edge,et al.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. , 1995, Radiology.

[46]  M A Helvie,et al.  Bilateral breast cancer: early detection with mammography. , 1995, Radiology.

[47]  R. Hendrick,et al.  Imaging of the radiographically dense breast. , 1993, Radiology.

[48]  S. Groshen,et al.  Contralateral breast carcinoma: an assessment of risk and prognosis in stage I (T1N0M0) and stage II (T1N1M0) patients with 20-year follow-up. , 1989, Surgery.

[49]  H. Leis.  Managing the remaining breast , 1980, Cancer.